Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

Sanofi and Alloy Therapeutics enter central nervous system deal worth over $427m

The agreement allows Sanofi to use Alloy’s antisense platform for a central nervous system target

- PMLiVE

FDA accepts updated protocol for Annovis’ phase 3 Alzheimer’s disease study

The company hopes the revised protocol will accelerate the development timeline of buntanetap

- PMLiVE

A Sparkling Achievement: Sarah Atwood Celebrated as a 2024 CPD Forty Under 40

For Sarah Atwood, MPH, the proudest moment of her incredible career in education and instructional design is happening right now. Atwood is an instructional designer with a public health lens...

Medscape Education

- PMLiVE

Bristol Myers Squibb’s Sotyktu shows promise in phase 3 psoriatic arthritis trials

The immune-mediated disease affects approximately 30% of people living with psoriasis

- PMLiVE

MHRA approves Italfarmaco’s Duvyzat to treat Duchenne muscular dystrophy

The severe neuromuscular disease affects approximately 2,500 people in the UK

- PMLiVE

Axsome announces positive results from phase 3 Alzheimer’s disease programme

The neurodegenerative disease affects approximately seven million people in the US

- PMLiVE

Sanofi and SK bioscience expand pneumococcal vaccine collaboration

The partners’ 21-valent paediatric vaccine entered late-stage clinical development last month

- PMLiVE

Prostate cancer blood test with ‘unprecedented accuracy’ cuts biopsies by 50%

There is currently no national screening programme for prostate cancer in the UK

- PMLiVE

Publicis Health appoints Annabelle Sandeman as chief growth officer in UK

Sandeman previously served as global head of commercial strategy at Huntsworth Health, now Inizio

- PMLiVE

Roche gains rights to Innovent Biologics’ ADC candidate in deal worth over $1bn

IBI3009 targets an antigen significantly overexpressed in cancers including small cell lung cancer

- PMLiVE

Bristol Myers Squibb’s injectable Opdivo formulation granted FDA approval

Opdivo Qvantig can be administered in three to five minutes compared to 30 minutes for the drug’s IV form

- PMLiVE

J&J expands atopic dermatitis pipeline with Kaken Pharmaceutical licensing deal

The inflammatory skin disorder affects more than 9.6 million children and 16.5 million adults in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links